Patent dispute on a multiple sclerosis medication.
Shares of Biogen Inc. were trading up 1.5 percent early Tuesday afternoon after the Cambridge biotech’s patent on its top-selling multiple sclerosis treatment was upheld by a legal ruling.
The U.S. Patent Trial and Appeal Board rejected a patent challenge by Texas hedge fund manager Kyle Bass, who has been working for years to invalidate key intellectual property rights of Biogen and other biotechnology companies. A ruling in favor of the Bass-led Coalition for Affordable Drugs could have hurt Biogen’s revenue from the oral MS drug Tecfidera, which generated nearly $4 billion in sales last year.
Biogen settled part of a separate ongoing patent dispute with Denmark’s Forward Pharma A/S in January, agreeing to pay $1.2 billion to license Forward Pharma’s intellectual property covering an active ingredient in Tecfidera. Investors are awaiting a pending decision in a separate part of that case, in which Forward Pharma is seeking annual royalties from Biogen on the sale of Tecfidera.
|Read Full Article: Biogen wins patent ruling for its $4 billion multiple sclerosis treatment – The Boston Globe|